Cambridge-bound Baxter makes $1B license deal with Merrimack

Merrimack Pharmaceuticals’ successful trial results earlier this year for one of the hardest cancers to treat — pancreatic — has paid off in a big way with a deal with Baxter worth $100 million up front and as much as $1 billion in potential milestones, not including eventual royalties...